Programma finale completo - SIF - Università degli Studi di Torino
Programma finale completo - SIF - Università degli Studi di Torino
Programma finale completo - SIF - Università degli Studi di Torino
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
183. The cannabinoid WIN 55212 inhibits pancreatic amylase secretion via cholinergic<br />
suppression<br />
Agostini Simona, Broccardo M., Improta G., Petrella C., Linari G.<br />
Dept. of Human Physiology and Pharmacology. University “La Sapienza”, Rome<br />
184. Sera of celiac patients with neurological <strong>di</strong>sorders evoke a mitochondrial-dependent<br />
apoptosis in human SH-Sy5Y neuroblastoma cells<br />
Cervio Elisabetta*, Volta U.°, Verri M.*, Boschi F.*, Pastoris O.*, Granito A.°, De Giorgio R.^,<br />
Tonini M.*<br />
*Dept of Phys & Pharm Sci, Univ Pavia; Dept of °Int Med, Car<strong>di</strong>oangiol, Hepatol & ^Int Med &<br />
Gastroenterol, Univ of Bologna, Italy<br />
185. Expression and function of the bradykinin B1 receptor in normal and inflamed<br />
human gallbladder<br />
Andre Eunice 1 , Gazzieri D. 1 , Bardella E. 1 , Ferreira J. 3 , Mori M.A. 4 , Bader M. 4 , João B.C. 5 , De<br />
Giorgio R. 6 , Corinaldesi R. 6 , Geppetti P. 1 , Trevisani M. 1<br />
1 Pharmacology Unit, University of Ferrara, 3 Dep. of Chemistry, Universidade Federal de Santa<br />
Maria, 4 Max Delbrück Center for Molecular Me<strong>di</strong>cine, Berlin-Buch, 5 Dep. of Pharmacology,<br />
Universidade Federal de Santa Catarina, Florianópolis, 6 Dep. Int. Med. and Gastroent.,<br />
University of Bologna<br />
186. A community pharmacies survey on prevalence of constipation and risk factors for<br />
laxative use in the local health <strong>di</strong>stricts of Verbania and Messina<br />
Morreale Ilaria (1) , Salvo F. (1) , Polimeni G. (1) , Vighi E. (2) , Poggi L. (2) , Dossi G. (2) , Rossitto<br />
A. (3) , De Sarro A. (1) , Calapai G. (1) , Caputi A.P. (1)<br />
(1) Dep. Clin Experim Med and Pharmacol, University of Messina, Italy. (2) Local Health District<br />
N. 14 (Verbano/Cusino/Ossola), Verbania, Italy<br />
99<br />
Farmacologia del metabolismo e del sistema endocrino<br />
Poster 187 – 195<br />
187. Exenatide achieved equivalent glycemic control to insulin glargine with weight<br />
reduction, independently from baseline BMI, in metformin and sulfonylurea-treated<br />
type-2 <strong>di</strong>abetes<br />
Gentilella Raffaella 4 ; Heine R.J. 1 ; Van Gaal L.F. 2 ; Johns D. 3 ; Mihm .J. 3 ; Widel M.H. 3 ; Brodows<br />
R.G. 3<br />
1 Diabetes Center, Department of Endocrinology, VU University Me<strong>di</strong>cal Center, Amsterdam,<br />
The Netherlands; 2 Department of Diabetology, Metabolism and Clinical Nutrition, Faculty of<br />
Me<strong>di</strong>cine, University Hospital Antwerp, Belgium; 3 Lilly Research Laboratories, Eli Lilly and<br />
Company, In<strong>di</strong>anapolis, IN, USA; 4 Eli Lilly Italy, Florence, Italy<br />
188. Effects of exenatide compared with twice-daily biphasic insulin aspart in patients<br />
with type 2 <strong>di</strong>abetes using metformin and a sulphonylurea<br />
Gentilella Raffaella 5 , Nauck M.A. 1 , Duran Garcia S. 2 , Kim D. 3 , Johns D. 4 , Festa A. 4 , Trautmann<br />
M. 4<br />
1 Clinical Diabetology, Diabeteszentrum Bad Lauterberg, Germany, 2 Cátedra de Endocrinología,<br />
Hospital de Valme, Seville, Spain, 3 Amylin Pharmaceuticals, Inc., San Diego, United States,<br />
4 Lilly Research Laboratories, Eli Lilly and Company, In<strong>di</strong>anapolis, United States; 5 Eli Lilly Italy,<br />
Florence, Italy<br />
pag_dx.indd 1 30/05/2007 4.30.39
Change language